Bevacizumab Fails to Improve Angiosarcoma Outcomes With Paclitaxel

Article

Adding bevacizumab to paclitaxel did not improve outcomes in a phase II trial of patients with angiosarcoma.

Representation of bevacizumab molecule; source: Roche

Adding bevacizumab to paclitaxel did not improve outcomes in a phase II trial of patients with angiosarcoma. The combination was similarly active to paclitaxel monotherapy, but there was added toxicity with bevacizumab, suggesting further investigation is not warranted.

Angiosarcoma accounts for a small proportion of soft-tissue sarcomas (less than 2%), but outcomes with angiosarcoma are poor. Prior work has shown that angiogenesis plays a large role in angiosarcoma proliferation, suggesting angiogenesis inhibition could offer benefit.

The new study, led by Nicolas Penel, MD, PhD, of Centre Oscar Lambret in Lille, France, enrolled 52 patients and randomized 50 to either paclitaxel alone (26 patients) or paclitaxel in combination with bevacizumab (24 patients). Seventeen patients had visceral angiosarcoma, and 24 had radiation-induced angiosarcoma; the most common primary sites were the breast (49%) and the skin (12%). Patients in both groups were followed for a median of 21 months, and the results were published online ahead of print in the Journal of Clinical Oncology.

The primary objective was met in both groups: more than eight patients were progression free at 6 months (14 non-progressions in each group). The objective response rate at 3 months was 45.8% with monotherapy and 28% with the combination.

The median overall survival was 19.5 months with paclitaxel alone, compared with 15.9 months with the addition of bevacizumab.

Safety data was available for 48 patients. A reduction in paclitaxel dose was required in 8 monotherapy patients and in 14 combination-therapy patients. Grade 3/4 toxicity was experienced by 21.7% of monotherapy patients and by 44% of combination-therapy patients.

There were no drug-related serious adverse events (SAEs) in the paclitaxel alone group, but there were 10 SAEs in 8 patients in the bevacizumab group. One patient died due to an intestinal occlusion, which was deemed to be related to the study treatment.

“At the end of this trial, despite its non-comparative nature, we do not recommend the addition of bevacizumab to paclitaxel once per week for the treatment of advanced angiosarcoma,” the authors concluded.

Related Videos
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Related Content